BhavanaPothuriMD
Obstetrics & Gynecology • New York, NYGynecologic Oncology
Professor, Obstetrics & Gynecology, New York University School of Medicine Director, Gynecologic Oncology Clinical Trials
Dr. Pothuri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
New York, NY 10016Phone+1 212-731-6455Fax+1 212-731-5600
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 1999 - 2003
Main Line Health System/Lankenau Medical CenterResidency, Obstetrics and Gynecology, 1995 - 1999
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1995
Certifications & Licensure
NY State Medical License 2000 - 2025
PA State Medical License 1996 - 2002- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- NY Magazine Top Doctors 2018
- Top Doctors: New York Metro Area Castle Connolly, 2014-2018
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Start of enrollment: 2010 Jun 01
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors Start of enrollment: 2016 Mar 07
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2017 Jun 23
- Join now to see all
Publications & Presentations
PubMed
- Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley
Journal of Comparative Effectiveness Research. 2025-01-01 - Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials.Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk
Cancer Research Communications. 2024-12-05 - Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Thierry André, Angela Jain
British Journal of Clinical Pharmacology. 2024-11-08
Authored Content
- Articles & IssuesDecember 2018
Press Mentions
What Can We Do About Health Disparities in the Diagnosis and Treatment of Endometrial Cancer?August 27th, 2024- Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 11th, 2023
- Remove Fallopian Tubes to Prevent Ovarian Cancer, Research Group SaysFebruary 3rd, 2023
- Join now to see all
Committees
- Co-Chair, SGO COVID Task Force 2020 - Present
- Co-Chair, SGO COVID Task Force 2020 - Present
- Co-Chair, SGO COVID Task Force 2020 - Present
- Vice Chair, SGO Clinical Practice Committee 2018 - Present
- Secretary, NYU Langone Health Faculty Council 2018 - Present
- Co-Chair, SGO COVID Task Force 2020 - 2020
- Co-Chair, SGO COVID Task Force 2020 - 2020
- Co-Chair, SGO COVID Task Force 2020 - 2020
Professional Memberships
- Member
- Society of Gynecologic OncologyMember
- NY Obstetrical SocietyMember
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
